Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122353 · ClinicalTrials.gov registry record · Phase 1
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
A Phase 1 study, sponsored by Tolmar.
- Completed
- Registry status
- Phase 1
- Development phase
- 699
- Enrollment target
NCT03122353 is a Phase 1 study that has completed, run by Tolmar. The registered enrollment target is 699 participants.
The verdict
NCT03122353, a Phase 1 study, has completed, sponsored by Tolmar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 699 participants
- Enrollment target
Study Summary
This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to the RLD.
Interventions
- DRUG Placebo
- DRUG Taclonex
- DRUG Calcipotriene and betamethasone suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 699 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2017-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122353
The ClinicalTrials.gov registry entry for NCT03122353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 699 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tolmar, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03122353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122353 about?
NCT03122353 is a clinical study titled "BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis". This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to the RLD.
What is the current status of trial NCT03122353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 699 participants. The study started on 2017-04-11. Estimated completion is 2017-11-15.
What interventions are being tested in trial NCT03122353?
The interventions under investigation include: Placebo (DRUG), Taclonex (DRUG), Calcipotriene and betamethasone suspension (DRUG).
Who is sponsoring clinical trial NCT03122353?
This trial is sponsored by Tolmar, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.